Following a slump in August, which posted the lowest med-tech deal values of 2024, September bounced back with the highest ...

Booster Therapeutics is ready to open up a new arm of the proteasome after raising $15 million in seed funding to advance ...

Genentech Inc. didn’t need to wait until Thanksgiving for the U.S. FDA to make up its mind. More than a month ahead of its ...

Ceribell Inc. launched its initial public offering of more than 10.6 million shares of common stock at $17 and steadily saw ...

PDUFA date, the U.S. FDA has approved Genentech Inc.’s first-line breast cancer treatment Itovebi (inavolisib). Itovebi is to be combined with Pfizer Inc.’s palbociclib (Ibrance) and fulvestrant for ...

Clinical research has shown that patients with systemic lupus erythematosus (SLE) are more likely to develop cardiovascular ...

Keybioscience AG and Eli Lilly & Co. have agreed to extend their collaboration on the development of dual amylin and calcitonin receptor agonists (DACRAs), a new class of potential treatments for ...

The founding CEO of Alnylam Pharmaceuticals Inc. is now leading the charge with newly launched City Therapeutics Inc., which just completed a $135 million series A financing. City’s executive chair, ...

Endostart s.r.l obtained CE marking for the expanded use of its magnetic balloon system for use in endoscopic procedures, Endorail, to enteroscopy. The company believes that Endorail, which helps ...

Ibio Inc. has announced progress under its collaboration with Astralbio Inc. on a joint myostatin program for cardiometabolic disease and obesity. Ibio leveraged its technology to rapidly advance the ...

Gilead Sciences Inc. terminated a potential $785 million licensing deal with Yuhan Corp. inked in 2019 to develop metabolic dysfunction-associated steatohepatitis (MASH) therapies.

Purespring Therapeutics Ltd. has raised £80 million (US$104.6 million) in a series B, putting it on course to be the first to ...